GlassScriptPhysician profile
Katie Klee
NPI 1790159101
$14,411.46
in general payments reported to CMS, 2019-2025
34 companies · $3,351 in 2025
The $3,351 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,977 · 2022: $2,851 · 2023: $3,094 · 2024: $3,138 · 2025: $3,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,583.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,776.63 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $2,776.14 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,354.84 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $838.68 | 2021-2025 | Dupixent |
| Amgen INC. | $668.54 | 2021-2025 | Tezspire |
| Pfizer INC. | $663.15 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $599.63 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $589.02 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $430.91 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Grifols USA, LLC | $410.02 | 2021-2024 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $396.51 | 2021-2025 | Xolair |
| Optinose US, INC. | $328.69 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $276.67 | 2021-2023 | |
| Csl Behring | $274.97 | 2021-2025 | Haegarda, Andembry, Kcentra |
| Alk-Abello, INC | $263.04 | 2021-2023 | Grastek, Ragwitek, Odactra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $246.37 | 2021-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $211.56 | 2023-2024 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $185.93 | 2025 | Neffy |
| Leo Pharma INC. | $184.20 | 2022-2024 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.43 | 2021-2023 | Spiriva Respimat |
| Aimmune Therapeutics, INC. | $116.89 | 2021-2022 | |
| Incyte Corporation | $110.70 | 2022-2025 | Opzelura |
| Pharming Healthcare, INC. | $103.57 | 2021-2025 | Ruconest |
| Ionis Pharmaceuticals, INC. | $88.16 | 2025 | Dawnzera |
| Cycle Pharmaceuticals INC | $86.06 | 2025 | Sajazir |
| Lilly USA, LLC | $59.25 | 2024-2025 | Ebglyss, Taltz |
| Uswm, LLC | $42.76 | 2021 | |
| Greer Laboratories, INC. | $35.77 | 2021 | |
| Galderma Laboratories, L.P. | $33.62 | 2025 | Nemluvio |
| Covis Pharma Gmbh | $27.98 | 2021 | |
| Ani Pharmaceuticals, INC. | $24.54 | 2025 | Purified Cortrophin Gel |
| Organon LLC | $20.00 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $16.08 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.15 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Klee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.